Global Human Insulin Drugs and Delivery Devices Market Size, Trends and Growth Opportunity, By Product (Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices), Drug (Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics), By Delivery Device (Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles), Application (Type I Diabetes, Type II Diabetes), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) By Region and forecast till 2027.
Global Human Insulin Drugs and Delivery Devices Market 
Global Human Insulin Drugs and Delivery Devices Market was valued at USD 42.85 billion in 2021 and is slated to reach at USD 71.30 billion by 2027 at a CAGR of 6.97 % from 2022-2027.
Protein hormone insulin helps those who lack sufficient insulin production manage their blood sugar levels. Blood glucose levels are decreased by insulin via increasing glucose absorption into muscles and fatty tissues. It can be injected into the thighs, buttocks, arms, belly, or backs of the arms. Additionally, insulin not only helps with managing diabetes but also with treating its immediate consequences, such as hyperosmolar hyperglycemia and diabetic ketoacidosis. Some of the tools that assist in delivering insulin to the patient's body include insulin syringes, insulin pumps, insulin pens, insulin inhalers, and insulin jet injectors.
Market Drivers
One of the key factors driving the expansion of human insulin medications and delivery systems is the increased prevalence of diabetes, particularly type 2 diabetes. During the projected period, sedentary lifestyles and shifting eating habits will have an impact on the market's dynamics. The increase in healthcare spending, which helps to improve its infrastructure, is a crucial element influencing the growth rate of the market for human insulin medicines and delivery devices. Furthermore, increased awareness-raising initiatives by public and private groups will expand the market for human insulin medications and delivery technologies. Furthermore, a high disposable income and a favourable reimbursement scenario will grow the market for human insulin medications and delivery devices. Along with this, the growing elderly population and advancements in insulin device design will accelerate market expansion.
A rise in the quantity of R&D activities is another factor driving the market's expansion. This will present advantageous chances for the development of human insulin-related medications and delivery systems. Along with this, an increase in drug releases and approvals will speed up the market's expansion. The growth of human insulin medicines and delivery devices will also benefit from increased investments in the development of cutting-edge technology and an increase in the number of new markets over the predicted period.
Market Restraints
On the other hand, the high cost of producing delivery devices will limit the market's rate of expansion. The market for human insulin medications and delivery devices will face challenges due to a shortage of skilled workers and a lack of healthcare infrastructure in developing economies. Additionally, during the projected period, tight rules and changes for the approval of products as well as a lack of consumer awareness would serve as restraints and further limit the market's growth pace.
Impact of COVID-19
The World Health Organization (WHO) has declared the COVID-19 virus a public health emergency as a result of its global spread since its discovery in December 2019. Due to COVID-19, the supply chain for the raw materials required to create human insulin medications and delivery devices has been disrupted in a number of nations. The outbreak is also causing the market for human insulin prescriptions and delivery systems to contract, as the manufacturers of these products have slowed down production. Therefore, it is anticipated that COVID 19 will have a considerable impact on the market for human insulin medications and delivery devices.
Market Segmentation
Global Human Insulin Drugs and Delivery Devices Market is segmented into Product, Drug, Application, Delivery Device, End-User, Distribution Channel. By Product such as Human Insulin (HI) Drugs, Human Insulin (HI) Delivery Devices. By Drug such as Insulin Analogs and Biosimilar, Long-Acting Biosimilar, Rapid-Acting Biosimilar, Premixed Biosimilar, Human Insulin Biologics, Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics. By Application such as Type I Diabetes, Type II Diabetes. By Delivery Device such as Syringes, Pens, Disposable Pens, Reusable Pens, Pen Needles, Standard Pen Needles, Safety Pen Needles. By End-User such as Hospitals, Specialty Clinics, Homecare, Others. By Distribution Channel such as Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others.
Regional Analysis 
North America and Europe now hold a monopoly on the market for human insulin medicines and delivery systems, because diabetes is becoming more common in these regions, The market's growth rate in this region will also be boosted by the increased emphasis of major key players on revolutionary technology.  Asia-Pacific is predicted to expand during the projection period, Because of its growing population and increasing healthcare costs.
Key Players
This report includes a list of numerous Key Players, namely Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Biocon (India).
Market Taxonomy
By Product
•    Human Insulin (HI) Drugs
•    Human Insulin (HI) Delivery Devices
By Drug
•    Insulin Analogs and Biosimilar
•    Long-Acting Biosimilar
•    Rapid-Acting Biosimilar
•    Premixed Biosimilar
•    Human Insulin Biologics
•    Short-Acting Biologics
•    Intermediate-Acting Biologics
•    Premixed Biologics
By Application
•    Type I Diabetes
•    Type II Diabetes
By Delivery Device
•    Syringes
•    Pens
•    Disposable Pens
•    Reusable Pens
•    Pen Needles
•    Standard Pen Needles
•    Safety Pen Needles
By End-Users
•    Hospitals
•    Specialty Clinics
•    Homecare
•    Others
By Distribution Channel
•    Hospital Pharmacy
•    Retail Pharmacy
•    Online Pharmacy
•    Others
By Region
•    North America
•    Latin America
•    Europe
•    Asia Pacific
•    Middle East & Africa.

Global Human Insulin Drugs and Delivery Devices Market
1 Introduction    
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Human Insulin Drugs and Delivery Devices Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Human Insulin Drugs and Delivery Devices Market, By Product
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
5.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Product
5.3.1 Human Insulin (HI) Drugs
5.3.2 Human Insulin (HI) Delivery Devices
6 Global Human Insulin Drugs and Delivery Devices Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Application
6.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application
6.3.1 Type I Diabetes
6.3.2 Type II Diabetes
7 Global Human Insulin Drugs and Delivery Devices Market, By Drug 
7.1 Y-o-Y Growth Comparison, By Drug
7.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Drug 
7.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Drug
7.3.1 Insulin Analogs and Biosimilar
7.3.2 Long-Acting Biosimilar
7.3.3 Rapid-Acting Biosimilar
7.3.4 Premixed Biosimilar
7.3.5 Human Insulin Biologics
7.3.6 Short-Acting Biologics
7.3.7 Intermediate-Acting Biologics
7.3.8 Premixed Biologics
8 Global Human Insulin Drugs and Delivery Devices Market, By Delivery Device
8.1 Y-o-Y Growth Comparison, By Delivery Device
8.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Delivery Device
8.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
8.3.1 Syringes
8.3.2 Pens
8.3.3 Disposable Pens
8.3.4 Reusable Pens
8.3.5 Pen Needles
8.3.6 Standard Pen Needles
8.3.7 Safety Pen Needles
9 Global Human Insulin Drugs and Delivery Devices Market, By End-Users
9.1 Y-o-Y Growth Comparison, By End-Users
9.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By End-Users
9.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users 
9.3.1 Hospitals
9.3.2 Specialty Clinics
9.3.3 Homecare
9.3.4 Others
10 Global Human Insulin Drugs and Delivery Devices Market, By Distribution Channel
10.1 Y-o-Y Growth Comparison, By Distribution Channel
10.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Distribution Channel 
10.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Distribution Channel
10.3.1 Hospital Pharmacy
10.3.2 Retail Pharmacy
10.3.3 Online Pharmacy
10.3.4 Others
11 Global Human Insulin Drugs and Delivery Devices Market, By Region
11.1 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Region
11.2 Global Human Insulin Drugs and Delivery Devices Market Share Analysis, By Region
11.3 Global Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Region
12 North America Human Insulin Drugs and Delivery Devices Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 North America Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
12.3 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application
12.4 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Drug
12.5 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
12.6 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users
12.7 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Distribution Channel
12.8 North America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Country
12.8.1 U.S.
12.8.2 Canada
12.8.3 Mexico
13 Europe Human Insulin Drugs and Delivery Devices Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Europe Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
13.3 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application 
13.4 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Drug
13.5 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
13.6 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users
13.7 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Distribution Channel
13.8 Europe Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Country
13.8.1 Germany
13.8.2 France
13.8.3 UK
13.8.4 Rest of Europe
14 Asia Pacific Human Insulin Drugs and Delivery Devices Market Analysis and Forecast (2022-2027)
14.1 Introduction
14.2 Asia Pacific Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
14.3 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application 
14.4 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Drug
14.5 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
14.6 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users
14.7 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Distribution Channel
14.8 Asia Pacific Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Country
14.8.1 China    
14.8.2 Japan
14.8.3 India
14.8.4 Rest of Asia Pacific
15 Latin America Human Insulin Drugs and Delivery Devices Market Analysis and Forecast (2022-2027)
15.1 Introduction
15.2 Latin America Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
15.3 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application 
15.4 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Drug
15.5 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
15.6 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users
15.7 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Distribution Channel
15.8 Latin America Human Insulin Drugs and Delivery Devices Market Size and Forecast, Country
15.8.1 Brazil
15.8.2 Rest of Latin America
16 Middle East Human Insulin Drugs and Delivery Devices Market Analysis and Forecast (2022-2027)
16.1 Introduction
16.2 Middle East Human Insulin Drugs and Delivery Devices Market Share Analysis, By Product
16.3 Middle East Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Application 
16.4 Middle East Human Insulin Drugs and Delivery Devices Market Share Analysis, By Drug
16.5 Middle East Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Delivery Device
16.6 Middle East Human Insulin Drugs and Delivery Devices Market Size and Forecast, By End-Users
16.7 Middle East Human Insulin Drugs and Delivery Devices Market Share Analysis, By Distribution Channel
16.8 Middle East Human Insulin Drugs and Delivery Devices Market Size and Forecast, By Country
16.8.1 Saudi Arabia
16.8.2 UAE
16.8.3 Egypt
16.8.4 Kuwait
16.8.5 South Africa
17 Competitive Analysis
17.1 Competition Dashboard
17.2 Market share Analysis of Top Vendors
17.3 Key Development Strategies
18 Company Profiles
18.1 Mylan N.V.
18.1.1 Overview
18.1.2 Offerings
18.1.3 Key Financials
18.1.4 Business Segment & Geographic Overview
18.1.5 Key Market Developments
18.1.6 Key Strategies
18.2 Teva Pharmaceutical Industries Ltd.
18.2.1 Overview
18.2.2 Offerings
18.2.3 Key Financials
18.2.4 Business Segment & Geographic Overview
18.2.5 Key Market Developments
18.2.6 Key Strategies
18.3 Sanofi
18.3.1 Overview
18.3.2 Offerings
18.3.3 Key Financials
18.3.4 Business Segment & Geographic Overview
18.3.5 Key Market Developments
18.3.6 Key Strategies
18.4 Novartis AG
18.4.1 Overview
18.4.2 Offerings
18.4.3 Key Financials
18.4.4 Business Segment & Geographic Overview
18.4.5 Key Market Developments
18.4.6 Key Strategies
18.5 Bayer AG 
18.5.1 Overview
18.5.2 Offerings
18.5.3 Key Financials
18.5.4 Business Segment & Geographic Overview
18.5.5 Key Market Developments
18.5.6 Key Strategies
18.6 Lilly 
18.6.1 Overview
18.6.2 Offerings
18.6.3 Key Financials
18.6.4 Business Segment & Geographic Overview
18.6.5 Key Market Developments
18.6.6 Key Strategies
18.7 Merck & Co., Inc
18.7.1 Overview
18.7.2 Offerings
18.7.3 Key Financials
18.7.4 Business Segment & Geographic Overview
18.7.5 Key Market Developments
18.7.6 Key Strategies    
18.8 AstraZeneca
18.8.1 Overview
18.8.2 Offerings
18.8.3 Key Financials
18.8.4 Business Segment & Geographic Overview
18.8.5 Key Market Developments
18.8.6 Key Strategies
18.9 Johnson & Johnson Private Limited
18.9.1 Overview
18.9.2 Offerings
18.9.3 Key Financials
18.9.4 Business Segment & Geographic Overview
18.9.5 Key Market Developments
18.9.6 Key Strategies
18.10 Biocon 
18.10.1 Overview
18.10.2 Offerings
18.10.3 Key Financials
18.10.4 Business Segment & Geographic Overview
18.10.5 Key Market Developments
18.10.6 Key Strategies